Jul 21, 2025 8:00am EDT ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
Jun 17, 2025 7:00am EDT ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Mar 31, 2025 7:00am EDT ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
Mar 24, 2025 7:00am EDT ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
Mar 13, 2025 7:00am EDT ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
Feb 25, 2025 7:00am EST ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
Jan 29, 2025 7:30am EST ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
Jan 10, 2025 7:00am EST ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease